Fenwick Represents DexCom in its $350 Million Convertible Senior Notes Offering

Fenwick & West represented DexCom, Inc. (NASDAQ: DXCM), a developer of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers, in its offering of $350 million aggregate principal amount of 0.75% convertible senior notes due 2022. The notes were issued pursuant to an Indenture between DexCom and U.S. Bank National Association, as trustee, pursuant to Rule 144A under the Securities Act of 1933, as amended.

DexCom plans to use the net proceeds of the offering of the notes to repay $75 million of borrowings under its existing credit facility and the remainder for general corporate purposes and capital expenditures, including working capital needs and build-out of its manufacturing facility in Arizona.

The Fenwick transaction team was led by corporate partners David Michaels, Michael Brown and Robert Freedman, and included associates Julia Forbess, Amanda Baratz and Larry Suh.